DELFLEX- dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride solution
DELFLEX- dextrose monohydrate, sodium chloride, sodium lactate, calcium

DELFLEX- dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride solution

Fresenius Medical Care North America

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DELFLEX  $^{\$}$  safely and effectively. See full prescribing information for DELFLEX  $^{\$}$ 

**DELFLEX (dextrose) peritoneal dialysis solution** 

Initial U.S. Approval: 1984

DELFLEX Low Magnesium, Low Calcium (dextrose) peritoneal dialysis solution

Initial U.S. Approval: 1992

For treatment of chronic kidney failure. ( 1)

Eor intraperitoneal dialysis only (2)

For intraperitoneal dialysis only. (2)

----- DOSAGE FORMS AND STRENGTHS -----

DELFLEX solutions are available in multiple compositions, calculated osmolarity, pH, and ionic concentrations. See full prescribing information for detailed descriptions of each formulation. (3, 11)

CONTRAINDICATIONS

None (4)

### ------WARNINGS AND PRECAUTIONS ------

- Monitor patient for electrolyte, fluid, and nutrition imbalances. (5.1)
- Encapsulating Peritonitis Sclerosis (EPS) (5.2)
- Peritonitis: Initiate appropriate antimicrobial therapy (5.2)
- Monitor for Lactic Acidosis in patients at risk. (5.3)

.....ADVERSE REACTIONS .....

Adverse reactions may include peritonitis, catheter site infection, electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, disequilibrium syndrome, muscle cramping, abdominal pain, abdominal distension, and abdominal discomfort. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2023

### **FULL PRESCRIBING INFORMATION: CONTENTS\***

- 1. INDICATIONS AND USAGE
- 2. DOSAGE AND ADMINISTRATION
  - 2.1 Basic Dosing Information
  - 2.2 Administration Instructions
  - 2.3 Compatible Medications
- 3. DOSAGE FORMS AND STRENGTHS
- 4. CONTRAINDICATIONS
- 5. WARNINGS AND PRECAUTIONS
  - 5.1 Electrolyte, Fluid and Nutrition Imbalances
  - 5.2 Peritonitis and Encapsulating Peritoneal Sclerosis
  - 5.3 Lactic Acidosis
  - 5.4 Over Infusion
- 6. ADVERSE REACTIONS
- 8. USE IN SPECIFIC POPULATIONS
  - 8.1 Pregnancy
  - 8.2 Lactation
  - 8.4 Pediatric Use
- 11. DESCRIPTION
- 12. CLINICAL PHARMACOLOGY
  - 12.1 Mechanism of Action
  - 12.3 Pharmacokinetics
- 13. NONCLINICAL TOXICOLOGY
  - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 16. HOW SUPPLIED/STORAGE AND HANDLING
- 17. PATIENT COUNSELING INFORMATION
- \* Sections or subsections omitted from the full prescribing information are not listed.

### **FULL PRESCRIBING INFORMATION**

#### 1. INDICATIONS AND USAGE

DELFLEX® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis.

### 2. DOSAGE AND ADMINISTRATION

### 2.1 Basic Dosing Information

DELFLEX® is intended for intraperitoneal administration only. Not for intravenous or intra-arterial administration.

The mode of therapy, frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis should be selected by the physician responsible for the treatment of the individual patient.

Utilize the peritoneal dialysis solution with lowest level of osmolarity consistent with the fluid removal requirements for that exchange.

Do not store solutions containing additives.

#### 2.2 Administration Instructions

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not heat in a microwave oven.


### **Get Ready**

- 1. Clean work surface.
- 2. Gather supplies:
  - DELFLEX peritoneal dialysis bag(s).
  - Prescribed medication(s), if ordered by your healthcare provider.
  - Mask.

3.

### **PVC**


Tear the overwrap from the slit edge down the length of the inner bag to open.



Wipe away any moisture from the solution bags. Some opacity may be observed in the plastic of the bag and/or tubing and is due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.



Locate pull tabs on overwrap. Grasping one tab in each hand, pull outward, down the length of the inner bag to open.



Wipe away any moisture from the solution Wipe away any moisture from the solution hads. Some opacity may be observed in the solution hads.

- 4. After removing the overwrap, check your DELFLEX solution bag(s) for strength, clarity, amount, leaks, and expiration date. Do not use DELFLEX solution if leaks are found, the solution bag is damaged, and/or the solution is cloudy or discolored, or the product is expired. Color may vary from clear to slightly yellow but does not affect efficacy and may be used.
- 5. Visually check that the solution bag tubing is free from kinks. If kinks are present, straighten tubing to allow the solution to flow freely.

Note: Retain DELFLEX peritoneal dialysis bag sample for manufacturer evaluation and notify your healthcare provider if any of the above defects are found.

Note: DELFLEX peritoneal dialysis solutions utilize the Safe-Lock® Connection System. This unique system consists of two Safe-Lock connectors, one located on the administration port of the bag, and the mating connector is located on the cycler set. The Safe-Lock connectors were designed to reduce the potential risk of touch contamination of the internal connection components.

- 6. Put on mask. Wash your hands.
- 7. If you will be adding medications(s):
  - Clean hands (as per facility's protocol)
  - Clean the medication port as instructed by your healthcare provider.
  - Add the medicine(s).
  - Turn the bag upside down several times to mix the medicine(s).
- 8. To connect the bag(s) to the cycler set, unscrew the protective caps of the administration port and the cycler set solution line connector. Secure these two connectors with a twisting motion to lock in place, so that the cycler set connector is seated over the administration port O-ring to assure a firm and tight fit.
- 9. After completing Step 8, wait for the cycler prompt to break the administration port cone and initiate solution flow. Do this by placing the thumb firmly on the tube over the cone and pressing towards the outer wall of the tube and away from the bag.



- 10. Perform your treatment as prescribed.
- 11. At the end of your treatment, throw away the fluid and used set as instructed by your healthcare provider. In case of cloudiness, save the fluid and the used set and immediately contact your healthcare provider. Dispose of your empty solution bag according to your local recycling program. Empty solution bags may not be recyclable in your area.

### 2.3 Compatible Medications

Compatible medications can be added via the medication port [see Dosage and Administration (2.2)]. The following medications have demonstrated stability with DELFLEX solutions: cefazolin, ceftazidime, gentamicin, and vancomycin [see Clinical Pharmacology (12.3)].

### 3. DOSAGE FORMS AND STRENGTHS

DELFLEX peritoneal dialysis solutions are available in single-dose flexible bags comprised of either polyvinyl chloride (PVC), or a proprietary blend of polyolefins called Biofine®. All DELFLEX peritoneal dialysis solutions have overfills declared on the bag label.

DELFLEX peritoneal dialysis solutions are available in the sizes and formulations shown in Table 1.

Table 1. DELFLEX peritoneal dialysis solution sizes and formulations

2L

DELFLEX Standard with 1.5% Dextrose			Х	Х		Х	Х
DELFLEX Standard with 2.5% Dextrose			Х	Х		Х	Х
DELFLEX Low Magnesium, Low Calcium with 1.5% Dextrose	Х	Х	Х	Х	Х	Х	Х
DELFLEX Low Magnesium, Low Calcium with 2.5% Dextrose	Х	Х	Х	Х	Х	Х	Х
DELFLEX Low Magnesium, Low Calcium with 4.25% Dextrose	Х	Х	Х	Х	Х	Х	Х

### 4. CONTRAINDICATIONS

None.

### 5. WARNINGS AND PRECAUTIONS

### 5.1 Electrolyte, Fluid and Nutrition Imbalances

Peritoneal dialysis may affect a patient's protein, water-soluble vitamin, potassium, sodium, chloride, bicarbonate, and magnesium levels and volume status. Monitor electrolytes and blood chemistry periodically and take appropriate clinical action.

Potassium is omitted from DELFLEX solutions because dialysis may be performed to correct hyperkalemia. In situations where there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/L) may be indicated to prevent severe hypokalemia.

To avoid the risk of severe dehydration or hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with lowest level of osmolarity consistent with the fluid removal requirements for that exchange.

Significant loss of protein, amino acids and water-soluble vitamins may occur during peritoneal dialysis. Replacement therapy should be provided as necessary.

### 5.2 Peritonitis and Encapsulating Peritoneal Sclerosis

Infectious and aseptic peritonitis has been associated with peritoneal dialysis therapy. Following DELFLEX use, inspect the drained fluid for the presence of fibrin or cloudiness, which may indicate the presence of peritonitis. Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, which may result in abdominal pain and/or peritonitis. If peritonitis occurs, treat with appropriate therapy.

Encapsulating peritoneal sclerosis (EPS), sometimes fatal, is a complication of peritoneal dialysis therapy.

### 5.3 Lactic Acidosis

Monitor patients with conditions known to increase the risk of lactic acidosis [e.g., severe hypotension or sepsis that can be associated with acute kidney failure, inborn errors of metabolism, treatment with drugs such as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] for lactic acidosis before the start of treatment and during treatment with DELFLEX.

Solutions containing the lactate ion should be used with great care in patients with metabolic or respiratory alkalosis. Lactate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.

#### 5.4 Over Infusion

Over infusion of peritoneal dialysis solution volume into the peritoneal cavity may be characterized by abdominal distention, feeling of fullness and/or shortness of breath. Drain the peritoneal dialysis solution from the peritoneal cavity to treat over infusion.

### **6. ADVERSE REACTIONS**

Solution related adverse reactions may include peritonitis, catheter site infection, electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome, muscle cramping, abdominal pain, abdominal distension, and

#### 8. USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

### Risk Summary

DELFLEX solutions consist of electrolytes, lactate, and bicarbonate at physiological levels, and glucose to facilitate ultrafiltration. While there are no adequate and well controlled studies in pregnant women, appropriate administration of DELFLEX with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with DELFLEX.

The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

### 8.2 Lactation

### Risk Summary

The components of DELFLEX solutions are excreted in human milk. Appropriate administration of DELFEX solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant.

#### 8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

### 11. DESCRIPTION


The DELFLEX® peritoneal dialysis solutions (standard and low magnesium/low calcium) are sterile, non-pyrogenic formulations of dextrose and electrolytes in water for injection, USP, for use in peritoneal dialysis. These solutions do not contain antimicrobial agents or additional buffers. Composition, calculated osmolarity, pH, and ionic concentrations are shown in Table 2.

Table 2. Composition, calculated osmolarity, pH and ionic concentration

	Composition/100mL			Total	рН		Ionic Co	ncentration	(mEq/L)			
	Dextrose		Sodium		Magnesium			Sodium	Calcium	Magnesium	Chloride	Lactate
	Hydrous,			Chloride,		(mOsmoL/L)						
	USP (C		(C3H5NaO3)		USP (MgCl	(calc)	6.0)					
	<sub>6</sub> H <sub>12</sub> O <sub>6</sub> ·H <sub>2</sub> O)	(NaCI)		(CaCl <sub>2</sub> ·2H <sub>2</sub> O)	<sub>2</sub> -6H <sub>2</sub> 0)							
DELFLEX	011207			2 211 207								
Standard												
with 1.5%												
Dextrose	1.5 g	567 mg	392 mg	25.7 mg	15.2 mg	347	5.5	132	3.5	1.5	102	35
DELFLEX												
Standard with 2.5%	2.5 g	567 mg	392 mg	25.7 mg	15.2 mg	398	5.5	132	3.5	1.5	102	35
Dextrose												
DELFLEX												
Low												
Magnesium,												
Low												
Calcium												
with 1.5% Dextrose	1.5 g	538 mg	448 mg	18.4 mg	5.08 mg	344	5.5	132	2.5	0.5	95	40
DELFLEX	1.5 9	330 mg	440 mg	10.4 1119	3.00 mg	344	ر. ر	132	2.5	0.5	93	40
Low												
Magnesium,												
Low												
Calcium												
with 2.5%												

Dextrose	2.5 g	538 mg	448 mg	18.4 mg	5.08 mg	394	5.5	132	2.5	0.5	95	40
DELFLEX Low Magnesium, Low Calcium with 4.25% Dextrose	4.25g	538 mg	448 mg	18.4 mg	5.08 mg	483	5.5	132	2.5	0.5	95	40

Dextrose, USP, is chemically designated D-glucose monohydrate (C  $_6$ H  $_1$ 2O  $_6$  +H  $_2$ O) a hexose sugar freely soluble in water. The structural formula is shown here:



Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl 2•2H 2O) white fragments or granules freely soluble in water.

Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl  $_2$  •6H  $_2$ O) colorless flakes or crystals very soluble in water.

Sodium lactate solution, USP, is chemically designated (CH  $_3$ CH(OH)COONa), a 60% aqueous solution miscible in water.

Sodium chloride, USP, is chemically designated (NaCl), a white, crystalline compound freely soluble in water.

Water for injection, USP, is chemically designated (H 2O).

Hydrochloric Acid or Sodium Hydroxide may be added for pH adjustment. pH is  $5.5\pm0.5$ .

Exposure to temperatures above 25°C (77°F) during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. Since the inner bag is compounded from flexible plastic, water may permeate from the inner bag into the overwrap in quantities insufficient to affect the solution significantly. Solutions in contact with the plastic inner bag can cause certain chemical components of the bag to leach out in very small amounts; however, the safety of the plastic formulation is supported by biological tests for plastic containers.

### 12. CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

DELFLEX peritoneal dialysis solutions are hypertonic peritoneal dialysis solutions containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DELFLEX solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DELFLEX solutions contain electrolytes to facilitate the correction of acid-base and electrolyte abnormalities. DELFLEX solutions contain a buffer, lactate, to help normalize acid-base abnormalities.

### 12.3 Pharmacokinetics

### **Absorption**

Glucose can be rapidly absorbed from the peritoneal cavity by diffusion and appears quickly in the circulation due to the high glucose concentration gradient between DELFLEX solutions compared to blood capillary glucose level. Absorption per unit time will be the highest at the start of an exchange and decreases over time. The rate of glucose absorption will be dependent upon the transport characteristics of the patient's peritoneal membrane as determined by a peritoneal equilibration test (PET). Glucose absorption will also depend upon the concentration of glucose used for the exchange

and the length of the dwell. Transport of other molecules will be dependent upon the molecular size of the solute, the concentration gradient, and the effective peritoneal surface area as determined by the PET.

### Metabolism and Elimination

Glucose is metabolized by normal cellular pathways (i.e., glycolysis). Metabolism of lactate occurs in the liver and results in the generation of the bicarbonate. Glucose not absorbed during PD exchange procedure is removed by drainage of the PD solution from the peritoneal cavity.

### **Drug Interaction Studies**

### **Antibiotics**

No formal clinical drug interaction studies have been performed. In vitro studies of the following medications have demonstrated stability with DELFLEX solutions: cefazolin, ceftazidime, gentamicin, and vancomycin.

### 13. NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term animal studies with DELFLEX peritoneal dialysis solutions have not been performed to evaluate the carcinogenic potential, mutagenic potential or effect on fertility.

#### 16. HOW SUPPLIED/STORAGE AND HANDLING

DELFLEX peritoneal dialysis solutions are available in the sizes and formulations shown in Table 1 [see Dosage Forms and Strengths (3)].

		P۱	/C			Biofine $^{\mbox{\scriptsize $\mathbb{R}$}}$	
	2L	3L	5L	6L	3L	5L	6L
Standard			49230-	49230-		49230-	49230-
1.5% Dextrose			188-50	188-60		188-52	188-62
Standard			49230-	49230-		49230-	49230-
2.5% Dextrose			191-50	191-60		191-52	191-62
Low Mg/Low Ca	49230-	49230-	49230-	49230-	49230-	49230-	49230-
1.5% Dextrose	206-20	206-30	206-50	206-60	206-32	206-52	206-62
Low Mg/Low Ca	49230-	49230-	49230-	49230-	49230-	49230-	49230-
2.5% Dextrose	209-23	209-30	209-50	209-60	209-32	209-52	209-62
Low Mg/Low Ca	49230-	49230-	49230-	49230-	49230-	49230-	49230-
4.25% Dextrose	212-23	212-30	212-50	212-60	212-32	212-52	212-62

Table 3. DELFLEX peritoneal dialysis NDC designations

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (between 59°F and 86°F). See USP Controlled Room Temperature. Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

Keep DELFLEX and all medicines out of the reach of children.

### 17. PATIENT COUNSELING INFORMATION

Aseptic technique must be used throughout the procedure and at its termination in order to reduce the possibility of infection.

The solution bag should remain in the carton and the overwrap intact until time of use.

Use only after checking for strength, clarity, amount, leaks, and expiration date.

Advise patients that DELFLEX peritoneal dialysis solution should not be heated in a microwave oven.

Care should be taken to ensure that there is not any leakage around the catheter, since if not controlled, the leakage can create edema from subcutaneous infiltration of the dialysis solution. The leakage will also create an inaccurate fluid balance measurement. If any leakage is identified, advise the patient not to proceed with infusion and notify your



Fresenius Medical Care North America 920 Winter Street Waltham, MA 02451 1-800-323-5188

© 2020, 2022 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, triangle logo, DELFLEX, Safe-Lock, Biofine are trademarks of Fresenius Medical Care Holding, Inc. or affiliated companies.

### Principal Display Panel - 1.5% Dextrose 2000 mL Bag Label **DELFLEX**®


PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-20221 NDC 49230-206-20

2000 mL

(Approx. 90 mL excess)



### **DELFLEX®**

### PERITONEAL DIALYSIS SOLUTION WITH

1.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-20221

2000 mL

1.5 538 mg

NDC 49230-206-20

(Approx. 40 mL excess)

Each 100 mL contains:	
Dextrose, Hydrous, USP	
Sodium Chloride, USP	
Sodium Lactate	
Calairea Chlasida LICD	

448 mg 18.4 mg Calcium Chloride, USP Magnesium Chloride, USP 5.1 mg Water for Injection, USP q.s. pH 5.5 (5.0 - 6.0) 344 mOsmol/Liter (calculated) May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY. USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert. Rx only

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

DPL-113 PLASTIC 89-909-04 Rev 01/07

Fresenius Medical Care

Principal Display Panel - 1.5% Dextrose 3000 mL Bag Label **DELFLEX®** 

PERITONEAL DIALYSIS SOLUTION WITH

1.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-30321

NDC 49230-206-30

3000 mL

(Approx. 60 mL excess)



### **DELFLEX®**

### PERITONEAL DIALYSIS SOLUTION WITH

## 1.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-30321

3000 mL

NDC 49230-206-30

(Approx. 60 mL excess)

Each 100 mL contains:

 Dextrose, Hydrous, USP
 1.5 g

 Sodium Chloride, USP
 538 mg

 Sodium Lactate
 448 mg

 Calcium Chloride, USP
 18.4 mg

 Magnesium Chloride, USP
 5.1 mg

 Water for Injection, USP
 q,s,

 pH 5.5 (5.0 - 6.0)
 344 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.
USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician,

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert.

Rx only

DPL-113 PLASTIC 89-909-10 Rev 01/07

Fresenius Medical Care NA Waltham, MA 02451

1-800-323-5188

## Principal Display Panel - 1.5% Dextrose 5000 mL Bag Label DELFLEX $^{\circledR}$

Fresenius Medical Care

PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-50521

NDC 49230-206-50

5000 mL

(Approx. 100 mL excess)



### PERITONEAL DIALYSIS SOLUTION WITH

## 1.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT NO 044-50521

5000 mL

NDC 49230-206-50

(Approx. 100 mL excess)

Each 100 mL contains:

 Dextrose, Hydrous, USP
 1,5 g

 Sodium Chloride, USP
 538 mg

 Sodium Lactate
 448 mg

 Calcium Chloride, USP
 18.4 mg

 Magnesium Chloride, USP
 51 mg

 Water for Injection, USP
 q,s,

 pH 5,5 (5,0 - 6,0)
 344 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment,

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY, USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged, Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat, Protect From Freezing, See Insert,

Rx only

DPL-113 PLASTIC 89-909-13 Rev 01/07

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

## Principal Display Panel - 2.5% Dextrose 2000 mL Bag Label DELFLEX $^{\! \otimes}$

PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-20322

NDC 49230-209-23

2000 mL/3 Liter Bag (Approx. 40 mL excess)



### PERITONEAL DIALYSIS SOLUTION WITH

## 2.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-20322

2000 mL/3 Liter Bag

NDC 49230-209-23

(Approx. 40 mL excess)

Each 100 mL contains:

 Dextrose, Hydrous, USP
 2.5 g

 Sodium Chloride, USP
 538 mg

 Sodium Lactate
 448 mg

 Calcium Chloride, USP
 18.4 mg

 Magnesium Chloride, USP
 5.1 mg

 Water for Injection, USP
 q.s.

 pH 5.5 (5.0 - 6.0)
 394 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment,

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.

USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert.

Rx only

DPL-113 PLASTIC 89-909-05 Rev 01/07

Fresenius Medical Care

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

## Principal Display Panel - 2.5% Dextrose 3000 mL Bag Label DELFLEX $^{\circledR}$

PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-30322

NDC 49230-209-30

3000 mL

(Approx. 60 mL excess)



### PERITONEAL DIALYSIS SOLUTION WITH

## 2.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-30322

3000 mL

NDC 49230-209-30

(Approx. 60 mL excess)

#### Each 100 mL contains:

Dextrose, Hydrous, USP
Sodium Chloride, USP
Sodium Lactate
Calcium Chloride, USP
Magnesium Chloride, USP
Magnesium Chloride, USP
Water for Injection, USP
pH 5.5 (5.0 - 6.0)
May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

### STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.
USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C).
Avoid Excessive Heat. Protect From Freezing. See Insert.
Rx only

DPL-113 PLASTIC 89-909-11 Rev 01/07



Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

## Principal Display Panel - 2.5% Dextrose 5000 mL Bag Label DELFLEX $^{\circledR}$

PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-50522 NDC 49230-209-50

5000 mL

(Approx. 100 mL excess)



### PERITONEAL DIALYSIS SOLUTION

#### 2.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-50522

5000 mL

NDC 49230-209-50

(Approx. 100 mL excess)

Each 100 mL contains:

Dextrose, Hydrous, USP 2.5 Sodium Chloride, USP 538 mg Sodium Lactate 448 mg Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water for Injection, USP a.s. pH 5.5 (5.0 - 6.0) 394 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY. USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert. Rx only DPL-113 PLASTIC 89-909-14 Rev 01/07

Fresenius Medical Care

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

### Principal Display Panel - 4.25% Dextrose 2000 mL Bag Label **DELFLEX**®

PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-20324

NDC 49230-212-23

2000 mL/3 Liter Bag (Approx. 40 mL excess)



### PERITONEAL DIALYSIS SOLUTION WITH

### 4.25% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-20324

NDC 49230-212-23

2000 mL/3 Liter Bag (Approx. 40 mL excess)

Each 100 mL contains:

4,25 g Dextrose, Hydrous, USP Sodium Chloride, USP 538 mg Sodium Lactate 448 mg Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water for Injection, USP q.s. pH 5.5 (5.0 - 6.0) 483 mOsmol/Liter (calculated) May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter: Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC. FOR INTRAPERITONEAL ADMINISTRATION ONLY, USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat, Protect From Freezing, See Insert,

Rx only

DPL-113 PLASTIC 89-909-06 Rev 01/07

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

### Principal Display Panel - 4.25% Dextrose 3000 mL Bag Label **DELFLEX®**

PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-30324 NDC 49230-212-30

3000 mL

(Approx. 60 mL excess)



### PERITONEAL DIALYSIS SOLUTION WITH

## 4.25% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-30324

3000 mL

NDC 49230-212-30

(Approx. 60 mL excess)

Each 100 mL contains:

 Dextrose, Hydrous, USP
 4.25 g

 Sodium Chloride, USP
 538 mg

 Sodium Lactate
 448 mg

 Calcium Chloride, USP
 18.4 mg

 Magnesium Chloride, USP
 5.1 mg

 Water for Injection, USP
 q.s.

 pH 5.5 (5.0 - 6.0)
 483 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment,

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.

USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C), Avoid Excessive Heat. Protect From Freezing. See Insert. Rx only DPL-113 PLASTIC 89-909-12 Rev 01/07



Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

## Principal Display Panel - 4.25% Dextrose 5000 mL Bag Label DELFLEX $^{\circledR}$

PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-50524

NDC 49230-212-50

5000 mL

(Approx. 100 mL excess)



### PERITONEAL DIALYSIS SOLUTION

## 4.25% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-50524

5000 mL

NDC 49230-212-50

(Approx. 100 mL excess)

### Each 100 mL contains:

 Dextrose, Hydrous, USP
 4,25 g

 Sodium Chloride, USP
 538 mg

 Sodium Lactate
 448 mg

 Calcium Chloride, USP
 18.4 mg

 Magnesium Chloride, USP
 5,1 mg

 Water for Injection, USP
 q.s.

 pH 5.5 (5.0 - 6.0)
 483 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC. FOR INTRAPERITONEAL ADMINISTRATION ONLY,

USE ASEPTIC TECHNIQUE, DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials,

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat, Protect From Freezing, See Insert,

Rx only

DPL-113 PLASTIC 89-909-15 Rev 01/07

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

## Principal Display Panel - 2.5% Dextrose 6000 mL Bag Label DELFLEX $\circledR$

PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-60622

NDC 49230-209-60

6000 mL

(Approx. 180 mL excess)

### PERITONEAL DIALYSIS SOLUTION WITH

### 2.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-60622

6000 mL

NDC 49230-209-60

(Approx. 180 mL excess)

### Each 100 mL contains:

Dextrose, Hydrous, USP 2.5 g 538 mg Sodium Chloride, USP Sodium Lactate 448 mg Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water for Injection, USP q.s. 394 mOsmol/Liter (calculated) pH 5.5 (5.0 - 6.0)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.

USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician. LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert.

Rx only DPL-113 PLASTIC 89-909-62 Rev 05/17

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

### Principal Display Panel - 4.25% Dextrose 6000 mL Bag Label **DELFLEX**®

PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-60624

NDC 49230-212-60

6000 mL

(Approx. 180 mL excess)

### PERITONEAL DIALYSIS SOLUTION WITH

### 4.25% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-60624

6000 ml

NDC 49230-212-60

(Approx. 180 mL excess)

### Fach 100 ml contains:

Dextrose, Hydrous, USP	4.25	g
Sodium Chloride, USP	538	mg
Sodium Lactate	448	mg
Calcium Chloride, USP	18.4	mg
Magnesium Chloride, USP	5.1	mg
Water for Injection, USP		q.s.
pH 5.5 (5.0 - 6.0) 483 mOsmol/Lite	er (calcula	ted)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

### STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.

USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert.

Rx only

DPL-113 PLASTIC 89-909-63 Rev 05/17



Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

Fresenius Medical Care

### Principal Display Panel - 1.5% Dextrose 6000 mL Bag Label **DELFLEX**®

PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE

LOW MAGNESIUM • LOW CALCIUM

CAT. NO. 044-60621

NDC 49230-206-60

6000 mL

(Approx. 180 mL excess)

### PERITONEAL DIALYSIS SOLUTION WITH

## 1.5% DEXTROSE LOW MAGNESIUM LOW CALCIUM

CAT. NO. 044-60621

6000 mL

NDC 49230-206-60

(Approx. 180 mL excess)

#### Each 100 mL contains:

Dextrose, Hydrous, USP 1.5 g
Sodium Chloride, USP 538 mg
Sodium Lactate 448 mg
Calcium Chloride, USP 18.4 mg
Magnesium Chloride, USP 5.1 mg
Water for Injection, USP q.s.
pH 5.5 (5.0 - 6.0) 344 mOsmol/Liter (calculated)

May contain Hydrochloric Acid or Sodium Hydroxide for pH adjustment.

Approximate Milliequivalents Per Liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

STERILE AND NON PYROGENIC.

FOR INTRAPERITONEAL ADMINISTRATION ONLY.
USE ASEPTIC TECHNIQUE. DOSAGE AS DIRECTED BY A PHYSICIAN.

Potassium Chloride to be added only under the direction of a physician.

LATEX: This product and its packaging does not contain latex materials.

CAUTION: Use only if solution is clear and container is undamaged. Discard any unused portion. Read package insert for full information.

Recommended Storage: Room Temperature (25°C). Avoid Excessive Heat. Protect From Freezing. See Insert.

Rx only

DPL-113 PLASTIC

STIC 89-909-61 Rev 05/17



Fresenius Medical Care

Fresenius Medical Care NA Waltham, MA 02451 1-800-323-5188

## Principal Display Panel - 1.5% Dextrose 3000 mL Bag Label DELFLEX $^{\circledR}$

Peritoneal Dialysis Solution in Biofine ® container

1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-30321

NDC 49230-206-32

3000 mL

(Approx. 90 mL Excess)

Peritoneal Dialysis Solution in Biofine® container

### 1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-30321 3000 mL NDC 49230-206-32 (Approx. 90 mL Excess)

#### Each 100 mL Contains:

Dextrose, Hydrous, USP1500 mgSodium Chloride, USP538 mgSodium Lactate, USP448 mgCalcium Chloride, USP18.4 mgMagnesium Chloride, USP5.1 mgWater For Injection, USPq.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\*

344 mOsmol/Liter (Calculated)

\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- For intraperitoneal
- administration only.
- Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
   Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-10 Rev 08/2022

## Principal Display Panel - 1.5% Dextrose 5000 mL Bag Label DELFLEX $^{\circledR}$

Peritoneal Dialysis Solution in Biofine <sup>®</sup> container

1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-50621 NDC 49230-206-52

5000 mL

(Approx. 150 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-50621 5000 mL NDC 49230-206-52 (Approx. 150 mL Excess)

### Each 100 mL Contains:

Dextrose, Hydrous, USP 1500 mg
Sodium Chloride, USP 538 mg
Sodium Lactate, USP 448 mg
Calcium Chloride, USP 18.4 mg
Magnesium Chloride, USP 5.1 mg
Water For Injection, USP q.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\* 344 mOsmol/Liter (Calculated)
\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- Sterile and non-pyrogenic.
- Use aseptic technique.
- For intraperitoneal administration only.
- Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
   Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- See prescribing information.

Rx Only 89-940-20 Rev 08/2022

## Principal Display Panel - 1.5% Dextrose 6000 mL Bag Label DELFLEX $^{\circledR}$

Peritoneal Dialysis Solution in Biofine ® container

1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-60621

6000 mL

(Approx. 180 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 1.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-60621 6000 mL NDC 49230-206-62 (Approx. 180 mL Excess)

#### Each 100 mL Contains:

Dextrose, Hydrous, USP 1500 mg Sodium Chloride, USP 538 ma Sodium Lactate, USP 448 mg Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water For Injection, USP q.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

344 mOsmol/Liter (Calculated)

\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- · For intraperitoneal administration only.
- · Potassium chloride to be added only under the direction of a physician.
- · Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
- Discard any unused portion. Recommended storage:
- store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-13 Rev 08/2022

### Principal Display Panel - 2.5% Dextrose 3000 mL Bag Label **DELFLEX**®

Peritoneal Dialysis Solution in Biofine ® container

2.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-30322 NDC 49230-209-32

3000 mL

(Approx. 90 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 2.5% Dextrose

Low Magnesium . Low Calcium

Cat. No. 077-30322 3000 mL (Approx. 90 mL Excess) NDC 49230-209-32

### Each 100 mL Contains:

Dextrose, Hydrous, USP 2500 mg 538 mg Sodium Chloride, USP 448 mg Sodium Lactate, USP Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water For Injection, USP q.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

394 mOsmol/Liter (Calculated) \*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic. · Use aseptic technique.
- · For intraperitoneal
- administration only.
- · Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged. Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- See prescribing information.

Rx Only 89-940-11 Rev 08/2022

### Principal Display Panel - 2.5% Dextrose 5000 mL Bag Label **DELFLEX**®

Peritoneal Dialysis Solution in Biofine ® container

2.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-50622

NDC 49230-209-52

5000 mL

(Approx. 150 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 2.5% Dextrose

Low Magnesium · Low Calcium

Cat. No. 077-50622 5000 mL NDC 49230-209-52 (Approx. 150 mL Excess)

### Each 100 mL Contains:

Dextrose, Hydrous, USP2500 mgSodium Chloride, USP538 mgSodium Lactate, USP448 mgCalcium Chloride, USP18.4 mgMagnesium Chloride, USP5.1 mgWater For Injection, USPq.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\*

394 mOsmol/Liter (Calculated)

\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- For intraperitoneal administration only.
- Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
   Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-21 Rev 08/2022

## Principal Display Panel - 2.5% Dextrose 6000 mL Bag Label DELFLEX $^{\tiny{\circledR}}$

Peritoneal Dialysis Solution in Biofine <sup>®</sup> container

2.5% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-60622

NDC 49230-209-62

6000 mL

(Approx. 180 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 2.5% Dextrose

Low Magnesium . Low Calcium

Cat. No. 077-60622 6000 mL NDC 49230-209-62 (Approx. 180 mL Excess)

### Each 100 mL Contains:

Dextrose, Hydrous, USP 2500 mg
Sodium Chloride, USP 538 mg
Sodium Lactate, USP 448 mg
Calcium Chloride, USP 18.4 mg
Magnesium Chloride, USP 5.1 mg
Water For Injection, USP q.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\* 394 mOsmol/Liter (Calculated)
\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- Dosage as directed by physician.
- Single dose container.
- Sterile and non-pyrogenic.
- Use aseptic technique.
- For intraperitoneal administration only.
- Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
   Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-14 Rev 08/2022

## Principal Display Panel - 4.25% Dextrose 3000 mL Bag Label DELFLEX $^{\circledR}$

Peritoneal Dialysis Solution in Biofine <sup>®</sup> container

4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-30324 NDC 49230-212-32

3000 mL

(Approx. 90 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-30324 3000 mL NDC 49230-212-32 (Approx. 90 mL Excess)

### Each 100 mL Contains:

Dextrose, Hydrous, USP4250 mgSodium Chloride, USP538 mgSodium Lactate, USP448 mgCalcium Chloride, USP18.4 mgMagnesium Chloride, USP5.1 mgWater For Injection, USPq.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\* 483 mOsmol/Liter (Calculated)
\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- For intraperitoneal administration only.
- Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged.
   Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- See prescribing information.

Rx Only 89-940-12 Rev 08/2022

## Principal Display Panel - 4.25% Dextrose 5000 mL Bag Label DELFLEX $^{\circledR}$

Peritoneal Dialysis Solution in Biofine <sup>®</sup> container

4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-50624

NDC 49230-212-52

5000 mL

(Approx. 150 mL Excess)

Peritoneal Dialysis Solution in Biofine® container

### 4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-50624 5000 mL NDC 49230-212-52 (Approx. 150 mL Excess)

#### Each 100 mL Contains:

Dextrose, Hydrous, USP 4250 ma Sodium Chloride, USP 538 mg 448 mg Sodium Lactate, USP Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water For Injection, USP a.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\*

483 mOsmol/Liter (Calculated)

\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- · For intraperitoneal
- administration only.
- · Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged. Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-22 Rev 08/2022

### Principal Display Panel - 4.25% Dextrose 6000 mL Bag Label **DELFLEX®**

Peritoneal Dialysis Solution in Biofine ® container

4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-60624 NDC 49230-212-62

6000 mL

(Approx. 180 mL Excess)

### **DELFLEX®**

Peritoneal Dialysis Solution in Biofine® container

### 4.25% Dextrose

Low Magnesium • Low Calcium

Cat. No. 077-60624 6000 ml (Approx. 180 mL Excess) NDC 49230-212-62

### Each 100 mL Contains:

Dextrose, Hydrous, USP 4250 mg Sodium Chloride, USP 538 mg 448 ma Sodium Lactate, USP Calcium Chloride, USP 18.4 mg Magnesium Chloride, USP 5.1 mg Water For Injection, USP q.s.

Approximate milliequivalents per liter:

Sodium 132 Magnesium 0.5 Calcium 2.5 Chloride 95 Lactate 40

pH 5.5 (5.0 - 6.0)\*

483 mOsmol/Liter (Calculated)

\*sodium hydroxide or hydrochloric acid may have been used for pH adjustment.

- · Dosage as directed by physician.
- · Single dose container.
- · Sterile and non-pyrogenic.
- · Use aseptic technique.
- For intraperitoneal administration only.
- · Potassium chloride to be added only under the direction of a physician.
- Latex: this product and its packaging does not contain latex materials.
- Caution: use only if solution is clear and container is undamaged. Discard any unused portion.
- Recommended storage: store at room temperature (25°C); avoid excessive heat; and protect from freezing.
- · See prescribing information.

Rx Only 89-940-15 Rev 08/2022

### **DELFLEX**

dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride solution

#### **Product Information HUMAN PRESCRIPTION DRUG Product Type**

**Route of Administration** 

INTRAPERITONEAL

Item Code (Source)

NDC:49230-206

Active Ingredient/Active Moiety						
Ingredient Name	Basis of Strength	Strength				
<b>DEXTROSE MONOHYDRATE</b> (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	1.5 g in 100 mL				
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698)	SODIUM CHLORIDE	538 mg in 100 mL				
<b>SODIUM LACTATE</b> (UNII: TU7HW0W0QT) (SODIUM CATION - UNII:LYR4M0NH37, LACTIC ACID - UNII:33X04XA5AT)	SODIUM LACTATE	448 mg in 100 mL				
CALCIUM CHLORIDE (UNII: M4I0D6VV5M) (CALCIUM CATION - UNII:2M83C4R6ZB, CHLORIDE ION - UNII:Q32ZN48698)	CALCIUM CHLORIDE	18.4 mg in 100 mL				
MAGNESIUM CHLORIDE (UNII: 02F3473H90) (MAGNESIUM CATION - UNII:T6V3LHY838, CHLORIDE ION - UNII:Q32ZN48698)	MAGNESIUM CHLORIDE	5.08 mg in 100 mL				

Inactive Ingredients	
Ingredient Name	Strength
WATER (LINII: 0590F0KOOR)	

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:49230-206- 20	6 in 1 CARTON	08/19/1992	
1		2000 mL in 1 BAG; Type 0: Not a Combination Product		
2	NDC:49230-206- 30	4 in 1 CARTON	08/19/1992	
2		3000 mL in 1 BAG; Type 0: Not a Combination Product		
3	NDC:49230-206- 32	4 in 1 CARTON	08/19/1992	
3		3000 mL in 1 BAG; Type 0: Not a Combination Product		
4	NDC:49230-206- 50	2 in 1 CARTON	08/19/1992	
4		5000 mL in 1 BAG; Type 0: Not a Combination Product		
5	NDC:49230-206- 60	2 in 1 CARTON	08/19/1992	08/31/2023
5		6000 mL in 1 BAG; Type 0: Not a Combination Product		
6	NDC:49230-206- 62	2 in 1 CARTON	08/19/1992	
6		6000 mL in 1 BAG; Type 0: Not a Combination Product		
7	NDC:49230-206- 52	2 in 1 CARTON	08/19/1992	
7		5000 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information								
Application Number or Monograph Citation	Marketing Start Date	Marketing End Date						
IDA020171	08/19/1992							
	Application Number or Monograph Citation	Application Number or Monograph Citation Marketing Start Date						

dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride solution

Product Information							
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:49230-209				
Route of Administration							
Active Ingredient/Active Moiety							
Ing	redient Name	Basis Stren	Strength				

SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698)	SODIUM CHLORIDE	538 mg in 100 mL
SODIUM LACTATE (UNII: TU7HW0W0QT) (SODIUM CATION - UNII:LYR4M0NH37, LACTIC ACID - UNII:33X04XA5AT)	SODIUM LACTATE	448 mg in 100 mL
CALCIUM CHLORIDE (UNII: M4I0D6VV5M) (CALCIUM CATION - UNII:2M83C4R6ZB, CHLORIDE ION - UNII:Q32ZN48698)	CALCIUM CHLORIDE	18.4 mg in 100 mL
MAGNESIUM CHLORIDE (UNII: 02F3473H9O) (MAGNESIUM CATION - UNII:T6V3LHY838, CHLORIDE ION - UNII:Q32ZN48698)	MAGNESIUM CHLORIDE	5.08 mg in 100 mL
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	2.5 g in 100 mL

# Inactive Ingredients Ingredient Name Strength WATER (UNII: 059QF0KO0R)

P	Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:49230-209- 23	6 in 1 CARTON	08/19/1992			
1		2000 mL in 1 BAG; Type 0: Not a Combination Product				
2	NDC:49230-209- 30	4 in 1 CARTON	08/19/1992			
2		3000 mL in 1 BAG; Type 0: Not a Combination Product				
3	NDC:49230-209- 32	4 in 1 CARTON	08/19/1992			
3		3000 mL in 1 BAG; Type 0: Not a Combination Product				
4	NDC:49230-209- 50	2 in 1 CARTON	08/19/1992			
4		5000 mL in 1 BAG; Type 0: Not a Combination Product				
5	NDC:49230-209- 60	2 in 1 CARTON	08/19/1992	08/31/2023		
5		6000 mL in 1 BAG; Type 0: Not a Combination Product				
6	NDC:49230-209- 62	2 in 1 CARTON	08/19/1992			
6		6000 mL in 1 BAG; Type 0: Not a Combination Product				
7	NDC:49230-209- 52	2 in 1 CARTON	08/19/1992			
7		5000 mL in 1 BAG; Type 0: Not a Combination Product				

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA020171	08/19/1992	

### **DELFLEX**

dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride solution

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:49230-212	
Route of Administration	INTRAPERITONEAL			

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
<b>DEXTROSE MONOHYDRATE</b> (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:55L0G7R0OK)	DEXTROSE MONOHYDRATE	4.25 g in 100 mL	
SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698)	SODIUM CHLORIDE	538 mg in 100 mL	

SODIUM LACTATE (UNII: TU7HW0W0QT) (SODIUM CATION - UNII:LYR4M0NH37, LACTIC ACID - UNII:33X04XA5AT)	SODIUM LACTATE	448 mg in 100 mL
CALCIUM CHLORIDE (UNII: M4I0D6VV5M) (CALCIUM CATION - UNII:2M83C4R6ZB, CHLORIDE ION - UNII:Q32ZN48698)	CALCIUM CHLORIDE	18.4 mg in 100 mL
MAGNESIUM CHLORIDE (UNII: 02F3473H90) (MAGNESIUM CATION - UNII:T6V3LHY838, CHLORIDE ION - UNII:Q32ZN48698)	MAGNESIUM CHLORIDE	5.08 mg in 100 mL

# Inactive Ingredients Ingredient Name Strength WATER (UNII: 059QF0KOOR)

P	Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:49230-212- 23	6 in 1 CARTON	08/19/1992			
1		2000 mL in 1 BAG; Type 0: Not a Combination Product				
2	NDC:49230-212- 30	4 in 1 CARTON	08/19/1992			
2		3000 mL in 1 BAG; Type 0: Not a Combination Product				
3	NDC:49230-212- 32	4 in 1 CARTON	08/19/1992			
3		3000 mL in 1 BAG; Type 0: Not a Combination Product				
4	NDC:49230-212- 50	2 in 1 CARTON	08/19/1992			
4		5000 mL in 1 BAG; Type 0: Not a Combination Product				
5	NDC:49230-212- 60	2 in 1 CARTON	08/19/1992	08/31/2023		
5		6000 mL in 1 BAG; Type 0: Not a Combination Product				
6	NDC:49230-212- 62	2 in 1 CARTON	08/19/1992			
6		6000 mL in 1 BAG; Type 0: Not a Combination Product				
7	NDC:49230-212-	2 in 1 CARTON	08/19/1992			

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA020171	08/19/1992	

### Labeler - Fresenius Medical Care North America (958291411)

7

5000 mL in 1 BAG; Type 0: Not a Combination Product

Revised: 12/2024 Fresenius Medical Care North America